HomeNewsBusinessWill TCS rework its strategy to build its own products and platforms?

Will TCS rework its strategy to build its own products and platforms?

Products such as ignio and BaNCS have gained traction, especially in the wake of Covid-19. But it takes time for such efforts to pay off, say the experts

August 03, 2020 / 22:31 IST
Story continues below Advertisement

With the Covid pandemic wreaking havoc on normal life globally, Digital has never been as important as it is now for IT services providers. For many of their clients, Digital is the only way business can run and the IT companies’ recent results bear testimony to that.

TCS, India’s largest IT services provider, boasted deal wins worth $6.9 billion in the quarter ended June, a 15 percent year-on-year increase. The majority of the deals are in what IT companies call the Digital segment, which includes new-age services such as cloud.

Story continues below Advertisement

But unlike its global rival Accenture, and local peers such as Wipro, which in addition to building in-house products make acquisitions that complements its portfolio, TCS has been building digital products and platform solutions in-house for its clients. It would not be a stretch to say that the company’s robust digital portfolio has been built from scratch.

However, there are doubts over whether this in-house product and platform development strategy is working given that TCS’s growth continues to decline despite the digital portion growing.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show